News | March 13, 2025
Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Pfizer's decision is based on the totality of clinical data
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
The National Sickle Cell Anaemia Elimination Mission was launched on 1st July 2023 at Shahdol, Madhya Pradesh
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
We are achieving the target of developed India by making our young children healthy today
Subscribe To Our Newsletter & Stay Updated
